The complaint filed against the New York-based pharmaceutical firm centers on claims that leadership failed to disclose critical challenges facing its flagship veterinary portfolio. Plaintiffs allege that adoption of the canine pain treatment Librela decelerated sharply as clinicians reacted to FDA safety warnings regarding potential neurological complications.

Beyond safety concerns, the legal action asserts that Zoetis lost significant ground in the competitive landscape. According to the filing, the company’s parasiticide Simparica Trio surrendered market share to lower-priced rivals, while its dermatology mainstays, Apoquel and Cytopoint, faced mounting pressure from new market entrants. The Gross Law Firm, which is representing the class, maintains that these undisclosed vulnerabilities led to an artificial inflation of share prices. Shareholders seeking to participate in the recovery process are not required to serve as lead plaintiffs to remain eligible for potential compensation.